Our Recent Posts

Archive

Tags

Understanding the Relevance of Research Studies for GDD

This question comes up frequently with Gadolinium Deposition Disease sufferers and the reading of the literature on gadolinium. Understanding the literature is extremely difficult as well, even for experts in Radiology research and publication such as myself, as this work is very specific to certain areas of science - which are not my areas. The only studies that directly are relevant to GDD sufferers are studies actually performed on GDD sufferers. They would also need to match the clinical scenario. The number of studies to be truly meaningful should be atleast 100 patients, and to see if treatment or no treatment is better management, is to have matched sufferers: age, gender, underlying

Gadolinium Deposition Disease: To Treat or Not To Treat. That is the Question.

What should be clear to sufferers of GDD, although there is now a disease that is recognized, at least by a number of health care providers, there is no magic bullet for cure. I had shaking chills at night about 4 weeks ago, from suspected Lyme's Disease, and I took 4 ibuprofen pills, and the shaking chills, head-ache and fever went dramatically down after 30 minutes. I had to think: "too bad there is not a drug that causes such a dramatic response for GDD sufferers, with such a high level of safety, and low cost." I also then took a 7 day oral course of doxicycline, and I recovered completely. So complete cure for Lyme's disease, without much pain, cost or time involvement. Unfortunately th

Ligands/Chelators and Gadolinium Deposition Disease (GDD)

Much of my thinking regarding ligands/chelators and GDD are based on the early work that MR contrast agent companies, especially Schering, published on various Gd + ligand combinations and on the importance of thermodynamic and kinetic stability of Gd chelates. This same exercise can also be worked out with all other heavy metals and other cations such as Calcium. So I fundamentally am fond of ligands that have been explored as creating stable GBCA MR agents, and not so fond of agents that have either not been tested as ligands, or have shown poor thermodynamic stability. Stable chelates with high thermodynamic stability, which can be created in vivo, are therefore good chelators. Chelators

Heavy Metal Toxicity

Below I am posting symptoms derived from an article (see link) on heavy metal toxicity. As you can see these are essentially the identical symptoms reported in GDD. I have not in my listing of critical symptoms focused o a number of the described symptoms in this heavy metal toxicity listing, as I have considered these symptoms (GI disturbance, depression, visual disturbance) too non-specific at present to include as critical criteria. At this early stage, with so many doubters in orthodox medicine, I want to report a short list of distinctive and unusual symptoms, that make refuting the condition exceedingly difficult. One point which makes GDD interesting from a scientific point of view, i

Protein Abnormalities in GDD

There are a number of publications that have reported on protein abnormalities in the setting of gadolinium (Gd) toxicity. Specifically amyloid production, light chain protein disease, with implications for the development of abnormal protein-related dementias (eg: Alzheimer's) and malignant disease such as Multiple Myeloma (MM). What is the genesis for this abnormal protein production? I am certainly not an expert on protein production, so I am standing on somewhat shaky ground, but my opinion is that in part this may reflect how GBCAs are handled in vivo by the host. Injected GBCAs retained in the body generally appear in some combination of 3 forms: 1) the intact chelate (macrocyclics re

Gadolinium in Urine

Everyone who receives a GBCA retains some Gd. Realistically the ones who retain appreciable gadolinium are individuals who have received more than 1 ( 2+, 5+ when you can see in the brain in basal ganglia on T1 weighted images) GBCA enhanced MRI with linear nonionic agents. So the numbers I use for the US are that perhaps 10 - 50 million individuals have appreciable Gd in their system. Overall this group I refer to as Gadolinium Storage Condition (GSC). The remarkable thing is that the majority are not sick - despite the fact that chemists and toxicologists have realized since at least 1950 that free Gd is highly toxic. The explanation for this is, in part, that some retained Gd remains in t

 
  • Facebook
  • LinkedIn
  • Twitter

©2018 BY RICHARD SEMELKA, MD. PROUDLY CREATED WITH WIX.COM